对增加B7-H3成像的附体分子亲和力的方法进行比较:二分化和亲和力成熟
Maryam Oroujeni1,2, Matilda Carlqvist3, Eva Ryer3
1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden. maryam.oroujeni@igp.uu.se.
EJNMMI radiopharmacy and chemistry
|April 16, 2024
概括
针对B7-H3的Dimeric Affibody分子表现出增强的亲和力,但没有改善瘤成像对比度. 较大的分子大小否定了放射性核素成像应用中增强结合的好处.
科学领域:
- 生物医学成像学 生物医学成像学
- 分子成像学分子成像学
- 亲密关系成熟期的到期.
背景情况:
- 放射性核素分子成像可视化分子标表达.
- 亲体分子是放射性核素瘤成像的有希望的支架.
- B7-H3在恶性瘤中过度表达,使其成为成像和治疗分层的目标.
研究的目的:
- 测试抗B7-H3亲体分子的二维格式是否会增加明显亲和力并改善成像对比度.
- 研究二分化作为一种替代亲和力成熟的方法,以增强Affibody分子的特性.
主要方法:
- 产生了两维变体的抗B7-H3亲体分子.
- 标有技术-99m (99mTc) 的变种.
- 评估了对表达B7-H3细胞的结合亲和力和体外特异性.
- 在B7-H3表达异种移植的小鼠中进行生物分布研究.
主要成果:
- 这两种二次变异 ([99mTc]Tc-ZAC12*-ZAC12*-GGGC和[99mTc]Tc-ZAC12*-ZTAQ_3-GGGC) 都显示出与表达B7-H3的细胞的特定结合.
- [99mTc]Tc-ZAC12*-ZAC12*-GGGC表现出亚纳米系亲和力 (KD1=0.28 ± 0.10 nM),比[99mTc]Tc-ZAC12*-ZTAQ_3-GGGC (KD=2.1 ± 0.9 nM) 高出7.6倍.
- 这两种二极体都显示出较低的瘤吸收率和瘤与器官的比率,相比于单体SYNT-179 Affibody分子在体内.
结论:
- 通过二分化增加的功能亲和力没有克服成像增加的分子大小的限制.
- 分化可能不是改善B7-H3 Affibody分子基放射性核素成像对比度的最佳策略.
关键词:
附体分子分子 附体分子亲和度成熟,技术-99m (99mTc) 的时间.B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3变质化变质化是指变质化.异种移植的SKOV-3异种移植在SPECT/CT成像中使用.更多相关视频
07:23Using High Content Imaging to Quantify Target Engagement in Adherent Cells
Published on: November 29, 2018
8.6K
10:17Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
Published on: January 14, 2020
7.8K
相关概念视频
Affinity and Avidity
35.5K
Overview
35.5K
Affinity Chromatography
3.1K
Affinity chromatography is a powerful technique extensively utilized for separating and purifying specific biomolecules from complex mixtures. It capitalizes on the highly selective binding between an analyte and its counterpart, such as antibody-antigen interactions. The counterpart is immobilized on the stationary phase, forming an affinity column. The stationary phase typically consists of solid support, such as agarose or porous glass beads, immobilizing the affinity ligand. The mobile...
3.1K
